Immunicum: Doctor takes the leadSwedish immuno-oncology play Immunicum AB has appointed Carlos de Sousa as its new CEO. Most recently, de Sousa worked as Chief Business Offer at Danish Zealand Pharma. more ➔
TxCell: Board ahoyImmunotherapy maker TxCell SA has appointed gene therapy expert Olivier Danos to its newly founded Scientific Advisory Board. Danos serves as Senior Vice President of Cell and Gene Therapy at Biogen … more ➔
GlaxoSmithKline: Insider AppointmentSix months ago, Andrew Witty, long-time CEO of Britains largest drug maker GlaxoSmithKline, announced he would retire in 2017. Now, GSK has named Emma Walmsley from inside the company as his successor. more ➔
Making a profitGerman molecular diagnostics specialist GNA Biosolutions GmbH has appointed Frank Krieg-Schneider as its Managing Director and CEO. Krieg-Schneider holds a PhD in molecular genetics from Mainz University … more ➔
Union builderSwedish Gyros Protein Technologies AB, which was formed in spring by merging nanoliter-scale immunoassay expert Gyros AB and peptide synthesis instrumentation and reagent provider Protein Technologies … more ➔
Bioelectric proGalvani Bioelectronics, the developer of bioelectronic medicines launched by GlaxoSmithKline and Alphabet’s life science play Verily (formerly Google Life Sciences) in early August, will have a bioelectronic … more ➔
Clinical development know-howFrench biopharma company Pharnext has appointed René Goedkoop as its new Chief Medical Officer. He joins the neurodegenerative disease specialist from Swiss Shogu Consulting SarL. more ➔
Immunotherapy pioneerMatthias Schroff, erstwhile CEO of Mologen, has taken over the helm of immunotherapy developer Vaximm AG. The Swiss-German company appointed him Chief Executive Officer in early September. more ➔
Overseas chiefSwedish clinical-stage biopharmaceutical company Aprea AB has named Christian Schade President and Chief Executive Officer. Before joining Aprea, Schade was CEO of US antiviral developer Novira Therapeutics, … more ➔
Vaccine proBrussels-based vaccine developer Univac has appointed a new CEO. In March, Stefano Malvolti joined Univac from Gavi, the Vaccine Alliance, where he was responsible for rolling out the vaccine development … more ➔
